Byotrol Secures EPA Approvals to Open Up North ...

Byotrol plc Byotrol plc ('the Company'), the AIM-quoted anti-microbial technology business has succeeded in obtaining approvals from the Environment Protection Agency ('EPA') in the United States for its technology to be used as a disinfectant, sanitiser and anti-microbial product. As part of this process, the EPA has approved the Company's claims that its technology is effective against a range of micro-organisms including Salmonella, Listeria, MRSA, E.coli and Avian Influenza. The EPA is the legislative body in the USA which is responsible for protecting human health and the environment. It regulates the approval of new technologies and products for use in these areas, and the performance claims that can legally be made on the product labels. The approvals follow a 7 month review process undertaken by the EPA and allows Byotrol to market disinfectants and sanitisers in the USA in the Company's initially targeted markets in healthcare, food and industrial technology. As set out in the Admission Document at the time of the AIM flotation, the EPA registration represents an important milestone in the Company's commercial strategy. The approvals allow the Company to market its products in concentrate form as a sanitiser and disinfectant for domestic use and for customers including hospitals and other healthcare institutions, food processing plants and agricultural facilities (including those subject to inspection by the US Department of Agriculture), restaurants, retail operations, hotels, public transport facilities, schools and universities, health clubs and spas. The Company has identified significant demand for its products in these areas based on discussions with a number of potential customers who have, until now, been unable to trial or acquire Byotrol's products without the EPA approvals that have now been obtained. This latest clearance for Byotrol's technology comes days after the Company was awarded CE Mark status for its products which allows it to market its technology to the medical sector on a pan European basis. Byotrol's Deputy Chairman Stephen Falder commented: 'The EPA acceptance of our anti-microbial claims is a very important springboard for key market sectors in the USA. We had originally anticipated that, at this stage, we would receive EPA acceptance for 5 to 7 market-specific claims but I am delighted to say that we have been able to obtain in excess of 20 approvals. Each approval allows us to sell our product in concentrate form to customers in a particular category or market sector. This is considerably ahead of our plan and a significant step forward for the Company following the detailed and complex work of the registration process.' According to the Global Biocides Report, the worldwide biocide market was valued in excess of $5.9 billion in 2005, with the USA the largest user of biocides, and is currently growing at around 4% per annum. According to David McRobbie, Chief Executive Officer of Byotrol plc, 'EPA approval is one of the most significant milestones in the Company's development to date. The approval, which was achieved on time and within budget, opens up the vast United States market for our technology and allows us to sell our products into a broader spectrum of sectors than we had originally anticipated. This builds on our progress in the UK and Europe where we have started to sell our products in a broad range of markets, from care homes and medical laboratories through to food processing and industrial coatings.' Financial calls to: Stephen Falder Byotrol plc 0870 609 4480 Or Oli Rayner Merchant Capital 0207 332 2200 Media calls to: Jim Rothnie McCann Erickson PR T: 01625 822540 E: jim.rothnie@europe.mccann.com

Companies

Byotrol (BYOT)
UK 100

Latest directors dealings